CoChat

Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Samuel, Michelle, Tardif, Jean-Claude, Bouabdallaoui, Nadia, Khairy, Paul, Dubé, Marie-Pierre, Blondeau, Lucie, Guertin, Marie-Claude · 2021 · Canadian Journal of Cardiology
Cited by 112

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND Reduction of inflammation with colchicine has emerged as a therapeutic option for secondary cardiovascular prevention in patients with coronary artery disease (CAD). Our objective was to consolidate evidence from randomized controlled trials (RCTs) evaluating the efficacy and safety of low-dose colchicine for secondary cardiovascular prevention among patients with CAD on standard medical therapy. METHODS RCTs comparing the incidence of cardiovascular events between patients with clinically manifest CAD randomized to colchicine versus placebo (or no colchicine) were included. The primary composite efficacy endpoint included cardiovascular mortality, myocardial infarction (MI), ischemic stroke, and urgent coronary revascularization. The DerSimonian and Laird random effects model was used to calculate pooled hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS Four RCTs, with a pooled sample size of 11,594 patients, were included (colchicine n=5774; placebo/no colchicine n=5820). Included RCTs studied populations with stable CAD (N=2) and acute coronary syndrome (N=2). Compared to placebo or no colchicine, colchicine was associated with a statistically significant reduction in the incidence of the primary composite endpoint [pooled HR 0.68 (95% CI 0.54-0.81); I2=37.7%]. The reduction in cardiovascular events among patients randomized to colchicine was driven by statistically significant reductions in MIs, ischemic strokes, and urgent coronary revascularizations (p<0.05 for all) and was relatively consistent among subgroups. The incidence of safety outcomes did not differ between groups (p>0.05). CONCLUSION In secondary cardiovascular prevention, the addition of low-dose colchicine to standard medical therapy reduces the incidence of major cardiovascular events, except cardiovascular mortality, when compared to standard medical therapy alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cjca.2020.10.006

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Samuel, M., Tardif, J.-C., Bouabdallaoui, N., Khairy, P., Dubé, M.-P., Blondeau, L., & Guertin, M.-C.
Venue
Canadian Journal of Cardiology
Publisher
Elsevier BV
Published
2021-05
Volume
37
Issue
5
Pages
776-785
ISSN
0828-282X (ISSN-L)
OpenAlex
W3092669347
Cited by
112
References
8
FWCI
4.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.